Literature DB >> 8761457

NMR solution conformation of heparin-derived tetrasaccharide.

D Mikhailov1, K H Mayo, I R Vlahov, T Toida, A Pervin, R J Linhardt.   

Abstract

The solution conformation of the homogeneous, heparin-derived tetrasaccharide delta UA2S(1-->4)-alpha-D-GlcNpS6S(1-->4)-alpha-L-IdoAp2S (1-->4)-alpha-D-GlcNpS6S (residues A, B, C and D respectively, where IdoA is iduronic acid) has been investigated by using 1H- and 13C-NMR. Ring conformations have been defined by J-coupling constants and inter-proton nuclear Overhauser effects (NOEs), and the orientation of one ring with respect to the other has been defined by inter-ring NOEs. NOE-based conformational modelling has been done by using the iterative relaxation matrix approach (IRMA), restrained molecular dynamics simulations and energy minimization to refine structures and to distinguish between minor structural differences and equilibria between various ring forms. Both glucosamine residues B and D are in the 4C1 chair conformation. The 6-O-sulphate group is oriented in the gauche-trans configuration in the D ring, whereas in the B ring the gauche-gauche rotomer predominates. Uronate (A) and iduronate (C) residues are mostly represented by 1H2 and 2S0 twisted boat forms, respectively, with small deviations in expected coupling constants and NOEs suggesting minor contributions from other A and C ring conformations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761457      PMCID: PMC1217593          DOI: 10.1042/bj3180093

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  One- and two-dimensional 13C-n.m.r. characterization of two series of oligosaccharides derived from porcine intestinal mucosal heparin by degradation with heparinase.

Authors:  P Gettins; A P Horne
Journal:  Carbohydr Res       Date:  1992-01       Impact factor: 2.104

2.  Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate.

Authors:  J E Turnbull; D G Fernig; Y Ke; M C Wilkinson; J T Gallagher
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

3.  Mapping and quantification of the major oligosaccharide components of heparin.

Authors:  R J Linhardt; K G Rice; Y S Kim; D L Lohse; H M Wang; D Loganathan
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

Review 4.  Structure and biological activity of heparin.

Authors:  B Casu
Journal:  Adv Carbohydr Chem Biochem       Date:  1985       Impact factor: 12.200

5.  Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources.

Authors:  D Loganathan; H M Wang; L M Mallis; R J Linhardt
Journal:  Biochemistry       Date:  1990-05-08       Impact factor: 3.162

6.  Structural studies on heparin. Tetrasaccharides obtained by heparinase degradation.

Authors:  A Linker; P Hovingh
Journal:  Carbohydr Res       Date:  1984-04-02       Impact factor: 2.104

7.  Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.

Authors:  D R Ferro; A Provasoli; M Ragazzi; B Casu; G Torri; V Bossennec; B Perly; P Sinaÿ; M Petitou; J Choay
Journal:  Carbohydr Res       Date:  1990-01-15       Impact factor: 2.104

8.  Reaction of unsaturated uronic acid residues with mercuric salts. Cleavage of the hyaluronic acid disaccharide 2-acetamido-2-deoxy-3-O-(beta-D-gluco-4-enepyranosyluronic acid)-D-glucose.

Authors:  U Ludwigs; A Elgavish; J D Esko; E Meezan; L Rodén
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

9.  Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue.

Authors:  G Torri; B Casu; G Gatti; M Petitou; J Choay; J C Jacquinet; P Sinaÿ
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

10.  Structure of heparin-derived tetrasaccharides.

Authors:  Z M Merchant; Y S Kim; K G Rice; R J Linhardt
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

View more
  7 in total

1.  NMR methods to monitor the enzymatic depolymerization of heparin.

Authors:  John F K Limtiaco; Szabolcs Beni; Christopher J Jones; Derek J Langeslay; Cynthia K Larive
Journal:  Anal Bioanal Chem       Date:  2010-09-04       Impact factor: 4.142

2.  NMR solution conformation of heparin-derived hexasaccharide.

Authors:  D Mikhailov; R J Linhardt; K H Mayo
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

3.  Designing "high-affinity, high-specificity" glycosaminoglycan sequences through computerized modeling.

Authors:  Nehru Viji Sankaranarayanan; Aurijit Sarkar; Umesh R Desai; Philip D Mosier
Journal:  Methods Mol Biol       Date:  2015

4.  Conformational analysis of a dermatan sulfate-derived tetrasaccharide by NMR, molecular modeling, and residual dipolar couplings.

Authors:  Alba Silipo; Zhenqing Zhang; F Javier Cañada; Antonio Molinaro; Robert J Linhardt; Jesús Jiménez-Barbero
Journal:  Chembiochem       Date:  2008-01-25       Impact factor: 3.164

Review 5.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

6.  Structure and mechanism of human UDP-xylose synthase: evidence for a promoting role of sugar ring distortion in a three-step catalytic conversion of UDP-glucuronic acid.

Authors:  Thomas Eixelsberger; Sabine Sykora; Sigrid Egger; Michael Brunsteiner; Kathryn L Kavanagh; Udo Oppermann; Lothar Brecker; Bernd Nidetzky
Journal:  J Biol Chem       Date:  2012-07-18       Impact factor: 5.157

7.  Residual dipolar coupling investigation of a heparin tetrasaccharide confirms the limited effect of flexibility of the iduronic acid on the molecular shape of heparin.

Authors:  Lan Jin; Milos Hricovíni; Jon A Deakin; Malcolm Lyon; Dusan Uhrín
Journal:  Glycobiology       Date:  2009-07-31       Impact factor: 4.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.